QuidelOrtho (NASDAQ:QDEL) Posts Quarterly Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL) released its quarterly earnings data on Wednesday. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Stock Down 3.7 %

Shares of NASDAQ QDEL opened at $39.94 on Thursday. QuidelOrtho has a 12-month low of $29.74 and a 12-month high of $68.85. The stock has a market cap of $2.69 billion, a P/E ratio of -1.43 and a beta of 0.08. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. The business’s fifty day simple moving average is $43.28 and its 200-day simple moving average is $42.36.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on QuidelOrtho in a report on Tuesday, December 10th. They set a “hold” rating and a $43.00 price target for the company. William Blair reaffirmed a “market perform” rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. Citigroup upgraded shares of QuidelOrtho from a “neutral” rating to a “buy” rating and lifted their price target for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. Finally, StockNews.com upgraded shares of QuidelOrtho from a “hold” rating to a “buy” rating in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, QuidelOrtho currently has an average rating of “Hold” and a consensus target price of $53.43.

Insider Buying and Selling

In related news, CEO Brian J. Blaser acquired 6,033 shares of the stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $41.42 per share, with a total value of $249,886.86. Following the completion of the transaction, the chief executive officer now owns 6,033 shares in the company, valued at $249,886.86. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by insiders.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.